Calibr at Scripps Research
Chan Beals has an extensive work experience in the field of pharmaceutical and biotech companies. Chan is currently serving as the Chief Medical Officer at Calibr at Scripps Research since January 2023. Prior to this, they held the position of SVP Translational Medicine at Autobahn Therapeutics, Inc. starting from January 2020.
From 2016 to 2020, Chan Beals worked as the Chief Medical Officer at Abide Therapeutics. Before that, they were the Vice President of Clinical Pharmacology at Merck from an unspecified date in 2012 to December 2015.
Chan Beals also has previous experience at Merck as the Senior Director and Head of Experimental Medicine from an unknown start date in 2006 to 2011. Before joining Merck, they held the position of Director at Pfizer from an unspecified date in 2002 to 2006. And prior to that, they worked as a Sr Scientist at ICOS Corporation from an unknown start date in 1997 to 2002.
Chan Beals studied at the Massachusetts Institute of Technology from 1979 to 1983, where they obtained a Bachelor of Science degree in Chemistry. Following that, Beals attended the University of Washington - School of Medicine from 1983 to 1990, where they earned a Doctor of Medicine (M.D.) degree with a focus on Biochemistry. Beals then pursued further education at the University of California, San Francisco from 1990 to 1997, specializing in Pediatrics and Pediatric Rheumatology but without obtaining a specific degree.
Calibr at Scripps Research
1 followers
The California Institute for Biomedical Research (Calibr) is a first-of-its-kind, nonprofit translational research institute dedicated to accelerating the next generation of medicines. Affiliated with Scripps Research—among the most innovative institutes worldwide—we spearhead drug discovery from a steady flow of pioneering science. Our self-sustaining model encourages broad and bold exploration with far-reaching goals, yet rapid transition of our most successful, high-impact programs into the clinic. We pursue audacious and imaginative ideas—bridging scientific and technological advances to develop new medicines for unmet medical needs. Our pipeline programs range from cancer to infectious diseases and from discovery to early clinical trial stages, all aimed at preventing disease and healing humans around the world. We bring together leaders in research, drug development, and business to answer important biological questions and develop new interventions to treat, cure, and prevent disease. Our infrastructure and expertise extend from high-throughput screening and protein engineering to pharmacology and clinical development. Calibr’s research space includes a newly renovated 35,000 square foot facility in La Jolla, CA, which houses over 100 interdisciplinary scientists and staff with state-of-the-art instrumentation. This infrastructure, combined with Calibr’s drug discovery expertise, enables projects rooted in novel therapeutic mechanisms to progress from the laboratory through preclinical development and ultimately to the clinic through commercial, federal, or foundation partnerships.